

1642



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 09/897,322

Group: 1642

Filing Date: July 2, 2001

Examiner: A. Holleran

Title: Dorsal Tissue Affecting Factor and Composition

RECEIVED
JUL 01 2003
TECH CENTER 1600/2

FIRST CLASS MAIL CERTIFICATE

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Bernadette B. Fahey
Bernadette B. Fahey

June 25, 2003
Date

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the Applicants' duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

☐ (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

☒ (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign

- ☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

- ☒ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

- ☐ (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

- ☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

- ☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

- ☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

REQUEST FOR TRANSFER OF REFERENCE COPIES

- ☒ Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN 09/167,874, filed October 7, 1998, be transferred to the subject application for consideration by the Examiner.

Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be \$180.. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-0650.

Respectfully submitted



Linda O. Palladino

Reg. No. 45,636

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400

CELL, Volume 67, issued November 15, 1991, Smith, W.C., and Harland, R.M., "Injected Xwnt-8 RNA Acts Early in Xenopus Embryos to Promote Formation of a Vegetal Dorsalizing Center", pp. 753-765.

EXAMINER
CONSIDERED

DATE

EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:



Linda O. Palladino
Reg. No. 45,636
Patent Agent for Applicants
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400



Creation date: 12-30-2003
Indexing Officer: LTOUCH - LY TOUCH
Team: OIPEBackFileIndexing
Dossier: 09897322

Legal Date: 08-06-2003

No.	Doccode	Number of pages
1	SRNT	1

Total number of pages: 1

Remarks:

Order of re-scan issued on